Literature DB >> 25702102

Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.

Ann E Walts1, James M Mirocha, Shikha Bose.   

Abstract

PURPOSE: Follicular variant of papillary thyroid carcinoma (FVPTC) is currently treated like conventional papillary thyroid carcinoma (cPTC). Recent reports indicate that encapsulated FVPTC behaves like follicular adenomas, while infiltrative FVPTC behaves like cPTC. This raises the possibility that histology and/or mutation status might help personalize management of FVPTC regarding extent of surgery, intensity of follow-up, and targeted therapy. This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600E mutation with lymph node (LN) metastasis and follow-up in FVPTC.
METHODS: Forty-eight FVPTC (21 with regional lymph node metastasis [LN+] and 27 with negative lymph nodes [LN-]) were reviewed. Demographics, tumor focality, size, circumscription, follicular architecture, lymphovascular invasion, extrathyroidal extension (ETE), and margin status were charted. Macrodissected formalin-fixed paraffin-embedded sections from 47 (21 LN+ and 26 LN-) cases were analyzed for BRAF V600E (1799T>A) mutation using real-time PCR. Correlations between the variables and LN status were calculated.
RESULTS: Sixty-two percent of cases with ETE demonstrated LN metastasis, while 59 % of cases with circumscribed tumors were LN-. In multivariable analysis, ETE and tumor size ≥1 cm were the best predictors of LN+ status, whereas in cases without ETE, the infiltrative pattern and tumor size provided the "best fit." Immunostains and BRAF mutation status were not helpful. All four tumors that recurred were LN+, with infiltrative borders, and lacked the BRAF mutation.
CONCLUSIONS: Tumor circumscription, extrathyroidal extension, and tumor size ≥ 1.0 cm are predictors of lymph node status in FVPTC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25702102     DOI: 10.1007/s00432-015-1939-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Neoplasms of the thyroid: classification, morphology, and treatment.

Authors:  J B HAZARD; G CRILE; R S DINSMORE; W A HAWK; R KENYON
Journal:  AMA Arch Pathol       Date:  1955-04

Review 2.  What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification.

Authors:  Gilbert H Daniels
Journal:  Endocr Pract       Date:  2011 Sep-Oct       Impact factor: 3.443

3.  Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.

Authors:  Michael Rivera; Julio Ricarte-Filho; Jeff Knauf; Ashok Shaha; Michael Tuttle; James A Fagin; Ronald A Ghossein
Journal:  Mod Pathol       Date:  2010-06-04       Impact factor: 7.842

4.  Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities.

Authors:  Sachin Gupta; Oluyomi Ajise; Linda Dultz; Beverly Wang; Daisuke Nonaka; Jennifer Ogilvie; Keith S Heller; Kepal N Patel
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-03

5.  Risk stratification of follicular variant of papillary thyroid carcinoma.

Authors:  Marina Vivero; Stefan Kraft; Justine A Barletta
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

6.  The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.

Authors:  Catarina Eloy; Joana Santos; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2011-07-28       Impact factor: 4.064

Review 7.  BRAF mutation in thyroid cancer.

Authors:  M Xing
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

8.  Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.

Authors:  Brooke E Howitt; Yonghui Jia; Lynette M Sholl; Justine A Barletta
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

9.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

10.  Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.

Authors:  J E Barroeta; Z W Baloch; P Lal; T L Pasha; P J Zhang; V A LiVolsi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

View more
  14 in total

1.  Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment.

Authors:  Lester Dr Thompson
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

2.  Risk factors for central neck lymph node metastases in follicular variant vs. classic papillary thyroid carcinoma.

Authors:  Marco Raffaelli; Carmela De Crea; Luca Sessa; Guido Fadda; Celestino Pio Lombardi; Rocco Bellantone
Journal:  Endocrine       Date:  2018-05-16       Impact factor: 3.633

3.  Sonographic features of follicular variant of papillary thyroid carcinoma (FV-PTC) and diagnostic performance of the 2017 ACR TI-RADS in FV-PTC.

Authors:  Fan Zhang; Wen Chen
Journal:  Endocrine       Date:  2020-01-09       Impact factor: 3.633

4.  Follicular morphological characteristics may be associated with invasion in follicular thyroid neoplasms with papillary-like nuclear features.

Authors:  Nuray Can; Mehmet Celik; Yavuz Atakan Sezer; Filiz Ozyilmaz; Semra Ayturk; Ebru Tastekin; Necdet Sut; Hakan Gurkan; Funda Ustun; Buket Yilmaz Bulbul; Sibel Guldiken; Fulya Oz Puyan
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

5.  Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.

Authors:  Atakan Sezer; Mehmet Celik; Buket Yilmaz Bulbul; Nuray Can; Ebru Tastekin; Semra Ayturk; Funda Ustun; Sibel Guldiken; Necdet Sut
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

6.  Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.

Authors:  Jing-Yong Song; Shi-Ran Sun; Fang Dong; Tao Huang; Bin Wu; Jing Zhou
Journal:  Curr Med Sci       Date:  2018-10-20

7.  The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Maurizio Martini; Sara Capodimonti; Diletta Sarti; Tonia Cenci; Mirna Bilotta; Guido Fadda; Luigi Maria Larocca
Journal:  Endocrine       Date:  2016-01-27       Impact factor: 3.633

8.  Follicular Variant of Papillary Thyroid Cancer with Bilateral Renal Metastases Discovered Incidentally During Work-Up of Primary Endometrial Cancer: A Rare Occurrence.

Authors:  Sandeep Singh Lubana; Navdeep Singh; Sandeep S Tuli; Tayyaba Bashir; Issac Sachmechi; Margaret M Kemeny
Journal:  Am J Case Rep       Date:  2015-07-16

9.  FOXE1 Mutation Screening in a Case with Cleft Lip, Hypothyroidism, and Thyroid Carcinoma: A New Syndrome?

Authors:  Hugo Mendieta-Zerón; Angélica Jiménez-Rosales; Carlos Jhovani Pérez-Amado; Silvia Jiménez-Morales
Journal:  Case Rep Genet       Date:  2017-08-27

10.  BRAF Testing in Multifocal Papillary Thyroid Carcinoma.

Authors:  Hillary Z Kimbrell; Andrew B Sholl; Swarnamala Ratnayaka; Shanker Japa; Michelle Lacey; Gandahari Carpio; Parisha Bhatia; Emad Kandil
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.